PAR-24-293-Full-Announcement.html

This document is a full announcement for the Federal Grant Opportunity titled "Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)".

The key details are: This funding opportunity is being reissued by the National Institutes of Health (NIH) to solicit applications from researchers developing diverse biotherapeutic modalities, including but not limited to antibodies, peptides, proteins, oligonucleotides, gene therapies, and cell therapies, for the treatment of nervous system and neuromuscular disorders. The funding instrument is a Cooperative Agreement, and eligible applicant types include non-profits, for-profit organizations, small businesses, higher education institutions, and state/local governments. The funding opportunity is expected to be published in Fall 2024 with an anticipated application due date in Winter 2025. It will utilize the UG3/UH3 activity code. The funding is provided under several NIH research grant programs, including Mental Health Research Grants, Alcohol Research Programs, Drug Use and Addiction Research Programs, and others related to environmental health, oral diseases, neurosciences, aging, and complementary/integrative health.